** Retail pharmacy franchisor Sigma Healthcare's SIG.AX shares are considered overvalued by Morningstar despite in-line earnings
** Full-year underlying EBIT growth more than doubled to A$68 mln was within co's forecast - Brokerage
** Adds revenue surged 46% to A$4.8 bln, mainly due to increased prescription volumes supplied to Chemist Warehouse $(CW)$
** However, gross margins in H2 shrank more than anticipated to 5.4% due to lower-margin prescription medicine sales - Morningstar
** Brokerage adds that SIG's market cap is similar to grocer Woolworths WOW.AX at over A$34 bln, suggesting a P/E ratio of 42 for fiscal 2029, including earnings from CW indicating overvaluation
** Morningstar maintains A$1.65/share fair value estimate
** Stock up 11.1% YTD
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.